Modulators of androgen and estrogen receptor activity

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Tis review focuses on signifcant recent fndings regarding modulators of androgen and estrogen receptor activity. Selective androgen receptor modulators (SARMs) interact with androgen receptors (ARs), and selective estrogen receptor modulators (SERMs) interact with estrogen receptors (ERs), with variable tissue selectivity. SERMs, which interact with both ERα and ERβ in a tissue-specifc manner to produce diverse outcomes in multiple tissues, continue to generate signifcant interest for clinical application. Development of SARMs for clinical application has been slower to date because of potential adverse efects, but these diverse compounds continue to be investigated for use in disorders in which modulation of the AR is important. SARMs have been investigated mostly at the basic and preclinical level to date, with few human clinical trials published. Tese compounds have been evaluated mostly for application in diferent stages of prostate cancer to date, but they hold promise for multiple other applications. Publication of the large STAR and RUTH clinical trials demonstrated that the SERMs tamoxifen and raloxifene have interesting similarities and diferences in tissues that contain ERs. Lasofoxifene, bazedoxifene, and arzoxifene are newer SERMs that have been demonstrated in clinical trials to more potently increase bone mineral density and lower serum cholesterol values than tamoxifen or raloxifene. Both SARMs and SERMs hold great promise for therapeutic use in multiple disorders in which tissue-specifc efects are mediated by their respective receptors.

Original languageEnglish (US)
Pages (from-to)275-294
Number of pages20
JournalCritical Reviews in Eukaryotic Gene Expression
Volume20
Issue number4
StatePublished - 2010

Fingerprint

Androgen Receptors
Selective Estrogen Receptor Modulators
Estrogens
Estrogen Receptors
Clinical Trials
Tamoxifen
LY 353381
Therapeutic Uses
Bone Density
Publications
Prostatic Neoplasms
Cholesterol
Serum

Keywords

  • Arzoxifene
  • Bazedoxifene
  • Breast cancer
  • Lasofoxifene
  • Osteoporosis
  • Prostate cancer
  • Raloxifene
  • SARM
  • SERM
  • Tamoxifen

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Modulators of androgen and estrogen receptor activity. / Clarke, Bart; Khosla, Sundeep.

In: Critical Reviews in Eukaryotic Gene Expression, Vol. 20, No. 4, 2010, p. 275-294.

Research output: Contribution to journalArticle

@article{6bf5aa0ee289486ab4bd33e6d1713acc,
title = "Modulators of androgen and estrogen receptor activity",
abstract = "Tis review focuses on signifcant recent fndings regarding modulators of androgen and estrogen receptor activity. Selective androgen receptor modulators (SARMs) interact with androgen receptors (ARs), and selective estrogen receptor modulators (SERMs) interact with estrogen receptors (ERs), with variable tissue selectivity. SERMs, which interact with both ERα and ERβ in a tissue-specifc manner to produce diverse outcomes in multiple tissues, continue to generate signifcant interest for clinical application. Development of SARMs for clinical application has been slower to date because of potential adverse efects, but these diverse compounds continue to be investigated for use in disorders in which modulation of the AR is important. SARMs have been investigated mostly at the basic and preclinical level to date, with few human clinical trials published. Tese compounds have been evaluated mostly for application in diferent stages of prostate cancer to date, but they hold promise for multiple other applications. Publication of the large STAR and RUTH clinical trials demonstrated that the SERMs tamoxifen and raloxifene have interesting similarities and diferences in tissues that contain ERs. Lasofoxifene, bazedoxifene, and arzoxifene are newer SERMs that have been demonstrated in clinical trials to more potently increase bone mineral density and lower serum cholesterol values than tamoxifen or raloxifene. Both SARMs and SERMs hold great promise for therapeutic use in multiple disorders in which tissue-specifc efects are mediated by their respective receptors.",
keywords = "Arzoxifene, Bazedoxifene, Breast cancer, Lasofoxifene, Osteoporosis, Prostate cancer, Raloxifene, SARM, SERM, Tamoxifen",
author = "Bart Clarke and Sundeep Khosla",
year = "2010",
language = "English (US)",
volume = "20",
pages = "275--294",
journal = "Critical Reviews in Eukaryotic Gene Expression",
issn = "1045-4403",
publisher = "Begell House Inc.",
number = "4",

}

TY - JOUR

T1 - Modulators of androgen and estrogen receptor activity

AU - Clarke, Bart

AU - Khosla, Sundeep

PY - 2010

Y1 - 2010

N2 - Tis review focuses on signifcant recent fndings regarding modulators of androgen and estrogen receptor activity. Selective androgen receptor modulators (SARMs) interact with androgen receptors (ARs), and selective estrogen receptor modulators (SERMs) interact with estrogen receptors (ERs), with variable tissue selectivity. SERMs, which interact with both ERα and ERβ in a tissue-specifc manner to produce diverse outcomes in multiple tissues, continue to generate signifcant interest for clinical application. Development of SARMs for clinical application has been slower to date because of potential adverse efects, but these diverse compounds continue to be investigated for use in disorders in which modulation of the AR is important. SARMs have been investigated mostly at the basic and preclinical level to date, with few human clinical trials published. Tese compounds have been evaluated mostly for application in diferent stages of prostate cancer to date, but they hold promise for multiple other applications. Publication of the large STAR and RUTH clinical trials demonstrated that the SERMs tamoxifen and raloxifene have interesting similarities and diferences in tissues that contain ERs. Lasofoxifene, bazedoxifene, and arzoxifene are newer SERMs that have been demonstrated in clinical trials to more potently increase bone mineral density and lower serum cholesterol values than tamoxifen or raloxifene. Both SARMs and SERMs hold great promise for therapeutic use in multiple disorders in which tissue-specifc efects are mediated by their respective receptors.

AB - Tis review focuses on signifcant recent fndings regarding modulators of androgen and estrogen receptor activity. Selective androgen receptor modulators (SARMs) interact with androgen receptors (ARs), and selective estrogen receptor modulators (SERMs) interact with estrogen receptors (ERs), with variable tissue selectivity. SERMs, which interact with both ERα and ERβ in a tissue-specifc manner to produce diverse outcomes in multiple tissues, continue to generate signifcant interest for clinical application. Development of SARMs for clinical application has been slower to date because of potential adverse efects, but these diverse compounds continue to be investigated for use in disorders in which modulation of the AR is important. SARMs have been investigated mostly at the basic and preclinical level to date, with few human clinical trials published. Tese compounds have been evaluated mostly for application in diferent stages of prostate cancer to date, but they hold promise for multiple other applications. Publication of the large STAR and RUTH clinical trials demonstrated that the SERMs tamoxifen and raloxifene have interesting similarities and diferences in tissues that contain ERs. Lasofoxifene, bazedoxifene, and arzoxifene are newer SERMs that have been demonstrated in clinical trials to more potently increase bone mineral density and lower serum cholesterol values than tamoxifen or raloxifene. Both SARMs and SERMs hold great promise for therapeutic use in multiple disorders in which tissue-specifc efects are mediated by their respective receptors.

KW - Arzoxifene

KW - Bazedoxifene

KW - Breast cancer

KW - Lasofoxifene

KW - Osteoporosis

KW - Prostate cancer

KW - Raloxifene

KW - SARM

KW - SERM

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=79955005388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955005388&partnerID=8YFLogxK

M3 - Article

C2 - 21395502

AN - SCOPUS:79955005388

VL - 20

SP - 275

EP - 294

JO - Critical Reviews in Eukaryotic Gene Expression

JF - Critical Reviews in Eukaryotic Gene Expression

SN - 1045-4403

IS - 4

ER -